- KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.Molecular oncology, 2020.
- Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancerSheng, Lin; Xiaoqin, Li; Ming, Lin; WenXiang, YueMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2021, 100(5): e24194.
- Expression-based, consistent biomarkers for prognosis and diagnosis in lung cancerM., Arroyo; R., Larrosa; J., Gómez-Maldonado; M. Á., Cobo; M. G., Claros; R., BautistaClinical & Translational Oncology, 2020, 22(10): 1867-1874.被引 1
期刊论文
Methylation of 14-3-3 sigma gene and prognostic significance of 14-3-3 sigma expression in non-small cell lung cancer
14阅读
